ArmaGen Overview
- Founded
- 2004
- Status
- Acquired/Merged
- Employees
- 15
- Latest Deal Type
- M&A
ArmaGen General Information
Description
Developer of therapies designed to address neurological complications. The company's pipeline of innovative therapies penetrates the blood-brain barrier to treat neurological complications of many diseases, including lysosomal storage disorders (LSDs), Alzheimer's and Parkinson's, enabling patients suffering from neurodegenerative disorders to get improved treatment.
Contact Information
Website
www.armagen.com
Formerly Known As
Neurogene Technologies, ArmaGen Technologies
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Office
- 26679 Agoura Road
- Suite 100
- Calabasas, CA 91302
- United States
+1 (818) 000-0000
ArmaGen Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 20-Apr-2020 | 0000 | Completed | Clinical Trials - General | ||
| 6. Later Stage VC (Series A2) | 01-Mar-2018 | 0000 | 0000 | 0000 | Completed | Clinical Trials - General |
| 5. Grant | 01-Apr-2015 | 000.00 | 0000 | Completed | Pre-Clinical Trials | |
| 4. Later Stage VC | 01-Jul-2014 | 0000 | 0000 | Completed | Pre-Clinical Trials | |
| 3. Later Stage VC (Series A) | 29-Nov-2012 | 0000 | 0000 | 0000 | Completed | Pre-Clinical Trials |
| 2. Debt - General | 01-Jan-2012 | $10M | $10M | Completed | Pre-Clinical Trials | |
| 1. Grant | 15-Aug-2008 | $2.4M | Completed | Pre-Clinical Trials |
ArmaGen Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A2 | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.0 | 00 | 00.00 | 000 |
| Series A1 | 0,000,000 | 00.000000 | 00.00 | 00.0 | 00.0 | 00 | 00.0 | 0.000 |
| Series A | 10,616,143 | $0.001000 | $0.13 | $1.6 | $1.6 | 1x | $1.6 | 24.03% |
ArmaGen Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of therapies designed to address neurological complications. The company's pipeline of innovative therapies pe
Drug Discovery
Calabasas, CA
15
As of 2018
0000
000000&0
0000
00000000
mpor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation
0000 000000000
Clarksville, MD
0
As of 0000
00.000
000000 0
00000000
e et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut
0000 000000000
Westmount, Canada
00
As of 0000
000.00
00000000000
000.00
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialArmaGen Competitors (21)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NeuroNascent | Venture Capital-Backed | Clarksville, MD | 0 | 00.000 | 000000 0 | |
| 000000000 | Venture Capital-Backed | Westmount, Canada | 00 | 000.00 | 00000000000 | 000.00 |
| 000000 00000000000 | Formerly VC-backed | Boston, MA | 000 | 00000 | 000000 - 000 | 00000 |
| 00000000 | Private Equity-Backed | Rye Brook, NY | 00 | 000.00 | 0000000 0000 | 000.00 |
| 0000000 0000000000 | Formerly VC-backed | Boston, MA | 0 | 00000 | 000000000 | 00000 |
ArmaGen Patents
ArmaGen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3908611-A1 | Methods and compositions for increasing galactosidase beta-1 activity in the cns | Pending | 08-Jan-2019 | 0000000000 | |
| EP-3898689-A1 | Purification of iduronate-2-sulfatase immunoglobulin fusion protein | Pending | 20-Dec-2018 | 0000000000 | |
| EP-3833689-A2 | Methods and compositions for increasing the activity in the cns of hexosaminidase a, acid sphingomyelinase, and palmitoyl-protein thioesterase 1 | Pending | 07-Aug-2018 | 00000000000 | |
| CA-3107749-A1 | Methods and compositions for increasing the activity in the cns of hexosaminidase a, acid sphingomyelinase, and palmitoyl-protein thioesterase 1 | Pending | 07-Aug-2018 | 00000000000 | |
| AU-2019317460-A1 | Methods and compositions for increasing the activity in the cns of hexosaminidase a, acid sphingomyelinase, and palmitoyl-protein thioesterase 1 | Pending | 07-Aug-2018 | A61K47/6815 |
ArmaGen Executive Team (11)
ArmaGen Board Members (15)
| Name | Representing | Role | Since |
|---|---|---|---|
| Masaji Matsuoka | Mitsui Global Investment | Board Observer | 000 0000 |
| Mathias Schmidt Ph.D | ArmaGen | Chief Executive Officer & Board Member | 000 0000 |
| William Pardridge MD | ArmaGen | Co-Founder, Chief Scientific Officer & Board Member | 000 0000 |
ArmaGen Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialArmaGen Former Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Boehringer Ingelheim Venture Fund | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Michael J. Fox Foundation | Limited Partner | 000 0000 | 000000 0 | ||
| Mitsui Global Investment | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Shire | Corporation | Minority | 000 0000 | 000000 0 | |
| Takeda Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 |